Aggressive ®bromatosis is a locally invasive soft tissue lesion. Seventy-®ve per cent of cases harbor a somatic mutation in either the APC or b-catenin genes, resulting in b-catenin protein stabilization. Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin synthesis that modulates the formation of colonic neoplasia, especially in cases due to mutations resulting in b-catenin stabilization. Human aggressive ®broma-toses and lesions from the Apc+/Apc1638N mouse (a murine model for Apc-driven ®bromatosis) demonstrated elevated COX-2 levels. COX-2 blockade either by the selective agent DFU or by non-selective COX blocking agents results in reduced proliferation in human tumor cell cultures. Breeding mice with Cox-27/7 mice resulted in no dierence in number of aggressive ®bromatoses formed, but in a smaller tumor size, while there was a decrease in number of GI lesions by 50%. Mice fed various COX blocking agents also showed a decline in tumor size. COX-2 expression was regulated by tcf-dependent transcription in this lesion. COX-2 partially regulates proliferation due to b-catenin stabilization in aggressive ®bromatosis. Although COX blockade alone does not cause tumor regression, this data suggests that it may have a role as an adjuvant therapy to slow tumor growth in this lesion. Oncogene (2001) 20, 451 ± 460.
Introduction
Aggressive ®bromatosis, also called desmoid tumour, is a locally invasive soft tissue lesion, composed of a clonal proliferation of spindle (®brocyte-like) cells (Alman et al., 1997a) . Although the cell of origin of aggressive ®bromatosis is not known, the cells most closely resemble ®broblasts (Lattes et al., 1980) . Seventy-®ve per cent of sporadic aggressive ®broma-toses harbor a somatic mutation in either the adenomatous polyposis coli (APC) or b-catenin genes, resulting in b-catenin protein stabilization (Li et al., 1998; Tejpar et al., 1999; Alman et al., 1997b) . There are phosphorylation sites near the amino terminus (a region encoded by nucleic acids in exon three) of bcatenin that are necessary for its ubiquitin-mediated degradation. A number of proteins, including GSK3b, axin, conductin and APC form a complex that regulates the phosphorylation of these sites. Typical mutations in APC result in a truncated protein that interferes with normal b-catenin regulatory function, and mutations in exon three of b-catenin remove phosphorylation sites resulting in protein stabilization. Stabilized b-catenin protein can bind to members of the tcf-lef family of architectural transcription factors, resulting in transactivation of transcription (Miller et al., 1999; Morin et al., 1997; Roose and Clevers, 1999) .
APC was initially found to be the gene responsible for the familial pre-neoplastic syndrome, familial adenomatous polyposis, which is characterized by the occurrence of hundreds of colonic polyps, and at least a 15% incidence of aggressive ®bromatoses, usually in an intra-abdominal location (Groden et al., 1991; Giardella et al., 1997; Kinzler et al., 1991) . Despite both b-catenin and APC being implicated in aggressive ®bromatoses and colonic neoplasia, there are distinct dierences in the molecular pathology of these lesions. There is a predominance of b-catenin mutations, as apposed to APC mutations in aggressive ®bromatosis (Tejpar et al., 1999; Sparks et al., 1998) . Germ-line mutations throughout the APC gene cause familial adenomatous polyposis, while germ-like mutations towards the 3' end of the APC gene cause familial in®ltrative ®bromatosis, characterized by relatively few colonic lesions, and a near universal occurrence of aggressive ®bromatosis (Eccles et al., 1996; Scott et al., 1996 ). An animal model of familial in®ltrative ®bromatosis, the Apc1638N mouse, carries a targeted mutation in the 3' end of the Apc gene. This mutation results in residual quantities of an otherwise functional truncated Apc protein. By 6 months of age, male Apc+/Apc1638N animals develop an average of 45 ®bromatoses, and females form an average of 16 ®bromatoses (Fodde et al., 1994; Smits et al., 1998; van der Houven van Oordt et al., 1999) .
Cyclooxygenase (COX), also called prostaglandin H synthase, catalyzes reactions necessary for the formation of prostaglandins from arachidonic acid. There are at least two isozymes of cyclooxygenase, COX-1 and COX-2. COX-1 is ubiquitously expressed, while COX-2 is induced by a variety of cellular stimuli, including growth factors and cytokines, and is classi®ed as an intermediate-early response gene. A role for COX in neoplasia was suggested by the ®nding that some neoplastic processes demonstrate elevated levels of arachidonic acid metabolites, such as prostaglandin E2 (PGE2). Many such neoplastic lesions, including colonic neoplasia, were found to express COX-2 (Williams et al., 1999) . Accordingly, a variety of pharmacological agents known as non-steroidal antiin¯ammatory drugs (NSAIDs) can eciently block cyclooxygenase activity and have bene®cial properties in colorectal cancer prevention. Recently, speci®c NSAIDs were developed that selectively block only COX-2, such as DFU (5,5-dimethyl-3-(3-¯uorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furon one) (Chan et al., 1997) and (Black et al., 1998) . COX-2 is implicated as a factor in tumor initiation in colonic neoplasia due to mutations in the APC gene. b-catenin stabilization may directly regulate COX-2 expression through activation of a lef-tcf transcription factor family member in colon cancer (Hsi et al., 1999; Mei et al., 1999) . Data from mouse models harboring germ-like Apc mutations, show that COX-2 blockade results in a signi®cant decrease in the number of gastrointestinal tumors formed (Oshima et al., 1996) .
The function of prostaglandins and cyclooxygenase in cancer pathogenesis is unclear. COX-2 regulation of proliferation (Sheng et al., 1997; Nguyen and Lee, 1993; Hial et al., 1977) , apoptosis (Tsujii and DuBois, 1995; Watson, 1998; Wolf and Laster, 1999) , and tumor-blood vessel interaction (Tsujii et al., 1998) has been suggested. Recent evidence implicates the prostaglandin receptor, peroxisome proliferator-activated receptor delta (PPAR-d), as a mediator in prostaglandin regulated tumorigenesis (He et al., 1999) . PPAR-d is a transcription factor, that is upregulated by bcatenin mediated transcription in colonic neoplasia. Sulindac, a non-steroidal anti-in¯ammatory drug, disrupts the ability of PPAR-d to bind its recognition sequence (He et al., 1999) .
The mechanism of action of NSAIDs in neoplasia is confounded by the demonstration of COX independent eects of these drugs (Ahnen, 1998; Abramson and Weissmann, 1989) . The growth of colon cancer cell lines lacking COX expression (Hanif et al., 1996) and transformed ®broblasts from COX de®cient mice (Zhang et al., 1999) is suppressed by NSAIDs. It is possible that NSAIDs act through a variety of pathways, altering cell behavior in neoplasia.
Anecdotal reports suggest that non-steroidal antiin¯ammatory drugs cause remission of aggressive ®bromatoses in patients (Lackner et al., 1997; Kirsch, 1991; Beliveau and Graham, 1984; Waddell et al., 1983) . Although previous studies suggest a role for prostaglandins and cyclooxygenase in colonic neoplasia (Williams et al., 1997 (Williams et al., , 1999 Oshima et al., 1996; He et al., 1999) , there are enough dierences between aggressive ®bromatosis and colonic neoplasia that data from one of these tumors can not be easily generalized to the other. However, anecdotal clinical data, and similarities in molecular etiology to colonic neoplasia, suggest that cyclooxygenase-two plays a role in the pathogenesis of aggressive ®bromatosis.
Results
Human aggressive ®bromatoses express COX-2 and produce prostaglandin E2. Using RT ± PCR, COX-2 expression was detected in 31 of 33 tumors. Northern analysis was performed on RNA extracted from tumor and normal tissue (®brous tissue obtained from the fascia at the resection margin) in six of the cases in which sucient RNA (at least 20 mg) was available, showing COX-2 expression in all six tumors, but only a small level of expression in one case of normal marginal tissue (Figure 1a and b) . Protein expression of COX-2 was demonstrated in these six tumors using Western analysis (Figure 1c) . Normal fascia cells demonstrated no expression of COX-2 (Figure 1d ). RT ± PCR data from 17 additional cases of the normal tissues from the tumor resection margins showed no expression of COX-2 in all but three samples. Prostaglandin E2 level was measured in primary cell Bromodeoxyuridine incorporation proliferation assays showed a signi®cant decline in proliferation with increasing concentration of the various COX blocking agents. Sulindac, indomethacin, and DFU were added to the media in 16 primary cell cultures derived from the human lesions, at various concentrations, the highest of which was shown to block 100% of COX-2 activity in vitro in a previous dose-response study (Chan et al., 1997) . A decline in proliferation was also demonstrated in the six normal ®broblast cultures derived from these patients, however, not to as great an extent as in the tumor derived cell cultures (Table   2 ). Although sulindac resulted in a larger decline in proliferation, this was not signi®cantly dierent than the decline observed with the other two drugs. In each case, after removal of media containing the drug and replacing normal media, the proliferation rate returned to baseline values, demonstrating the reversibility of the eect on proliferation. PGE2 levels were blocked by all of the drugs, declining to low levels at the highest concentration of each drug in each of the cell types (Table 1) . No signi®cant change of apoptosis was detected, despite using concentrations of the blocking agents ten times higher than that of the greatest concentrations utilized in the proliferation experiments, as demonstrated using both DNA laddering ( Figure 2 ) and a TUNEL assay.
Primary aggressive ®bromatosis cell cultures were used to demonstrate that b-catenin mediated tcfdependent transcription regulates COX-2 expression. DN tcf-4E binds the tcf consensus sequence, but prevents transcriptional activation by other transcription factors (Tetsu and McCormick, 1999) . COX-2 expression decreased when DN tcf-4E was transfected into a primary aggressive ®bromatosis cell culture, Figure 2 DNA ladder from cell cultures subjected to concentrations of COX blocking agents ten times higher than the maximum concentration used to produce the data in tables one and two. No evidence of DNA fragmentation is present in any of the samples. Positive and negative controls are loaded in the second and last lanes. Controls are from the manufacturer of the apoptosis detection kit compared to transfection of an empty vector ( Figure  3 ). Transfection eciency of DN tcf-4E was 25%, as measured using a green¯uorescent protein vector. COX-2 expression was also determined in the primary cell cultures using RT ± PCR. Expression was detected in all of the tumor derived cultures. The cultures derived from the normal ®broblasts also expressed COX-2 during the log phase of growth. Expression of the prostaglandin receptor and transcription factor, PPAR-d, was determined using RT ± PCR and Northern analysis in the lesions. PPARd expression was not detected in 22 of 33 tumors using RT ± PCR, while it was detected in all of the colon cancers. Aggressive ®bromatoses that did express PPAR-d did so at lower levels than did the colon cancer (Figure 4) .
These data show that most human aggressive ®bromatoses express COX-2, and that COX blockade results in decreased cell proliferation. However, an in vivo model is required to better determine the eect of COX blockade on tumor behaviour. For this reason, the Apc+/Apc1638N mouse was studied.
b-catenin, COX-2, and PPAR-d expression was analysed in the murine lesions to determine if the expression levels were similar to that observed in the human lesions. Loss of the wild-type APC allele has been demonstrated in some murine aggressive ®bro-matosis formed by the Apc+/Apc1638N mouse (Fodde et al., 1994) . The loss of the wild-type allele results in b-catenin stabilization in human lesions, but b-catenin protein levels were not previously studied in the murine lesions. Using Western analysis, the murine aggressive ®bromatoses showed a higher level of expression than the normal tissues ( Figure 5 ). Immunohistochemistry for b-catenin, con®rmed elevated protein expression by cells in the tumors, and demonstrated a cellular staining pattern similar to that previously reported for human lesions (Figure 6 ), in which b-catenin localized to the entire cell, rather than to the cell membrane (Li et al., 1998; Tejpar et al., 1999) . Thus, like human tumors, the murine lesions exhibit bcatenin protein stabilization. Western analysis showed that the murine lesions expressed COX-2, while normal ®brous tissue did not. Similar to the human tumors, PPAR-d was expressed at low levels in the murine aggressive ®bromatoses compared to murine gastrointestinal lesions and the SW480 colon cancer cell line (Figure 4) .
There was no dierence in the number of ®broma-toses formed between Apc+/Apc1638N-Cox2+/+ and Apc+/Apc1638N-Cox27/7 mice (13.5 on average in the Apc+/Apc1638N-Cox2+/+ male mice and 11.5 on average in the Apc+/Apc1638N-Cox7/7 male mice; and 6.3 on average in the Apc+/Apc1638N-Cox2+/+ female mice and 5.8 on average in the Apc+/Apc1638N-Cox27/7 female mice). However, the lesions formed in the Cox27/7 mice were of signi®cantly smaller dimeter than in the Cox2+/+ mice (1.2 mm with a standard deviation of 0.6 mm vs 2.2 mm with a standard deviation of 0.6 mm for the male mice as illustrated in Figure 7 , P=0.01 using the two-tailed t test, n=8 mice in each group; and 0.9 mm with a standard deviation of 0.6 mm vs 1.9 mm with a standard deviation of 0.5 mm for the female mice, P=0.05, n=8 mice in each group). This was in contrast to gastrointestinal lesions, for which the Cox27/7 mice produced roughly half the number of lesions (2.4 with a standard deviation of 1.2 vs 5.2 with a standard deviation of 2.2, P=0.01). Since the male and female mice develop a dierent numbers of ®bromatoses, but not dierent numbers of gastrointestinal lesions, the ®bromatoses were analysed separately for male and female mice, while gastrointestinal lesions were analysed in the male and female mice together. The mice fed sulindac showed no signi®cant dierence in number of ®bromatoses formed at six months of age compared to mice fed no drugs as control (34.7 vs 30.5). However, the average diameter of the ®bromatoses in the mice fed sulindac was signi®cantly smaller than the diameter of the ®broma-toses in the control mice (1.5 mm with a standard deviation of 1.0 mm vs 2.5 mm with a standard deviation of 1.6 mm, P=0.002 using the two-tailed t test). The mice fed MF-tricyclic resulted in no dierence in number of ®bromatoses, but in a trend Figure 5 Western analysis for b-catenin in a ®bromatosis from the Apc+/Apc1638N mouse, and normal ®brous tissue from the same animal. A greater amount of protein was loaded from the normal ®brous tissue, which is con®rmed by Western analysis on the same membrane using an antibody to alpha-actin. Lane one is protein extract from a ®bromatosis, and lane two is loaded with protein extract from normal ®brous tissue. b-catenin protein level is increased in the ®bromatosis Size of ®bromatoses formed by the male Apc+/ Apc1638N; COX2+/+ and male Apc+Apc1638N; COX27/7 mice. The mice expressing COX-2 form larger ®bromatoses towards a smaller tumor diameter compared to control mice (1.9 mm with a standard deviation of 1.2 mm vs 2.5 mm with a standard deviation of 1.6, P=0.07 using the two-tailed t test). DFU treatment resulted in no change in number or size of tumors (2.3 vs 2.5 mm diameter), however, only a negligible level of DFU was detected in the ®ve animals tested who were treated with this drug. Table 3 summarizes the results of the various COX blocking agents on the number and size of tumors formed by the Apc+/Apc1638N mouse.
Immunohistochemical techniques were used to determine dierences in proliferation, apoptosis, and tumor vascularity in the murine tumors. MIB-1 staining was used to determine dierences in cell proliferation, and showed a lower percentage of positively stained nuclei in the ®bromatoses in the COX-27/7 mice than in the COX2+/+ mice (4 vs 7% positively stained nuclei). However, this was not a statistically signi®cant dierence due to the large variability in percent MIB-1 staining in the tumor samples. No dierence in TUNEL staining (a measure of apoptosis), or in factor VIII staining (for vascularity) was detected.
Discussion
We demonstrated that COX-2 is expressed in the majority of aggressive ®bromatoses. In addition, these tumors produce elevated levels of the arachidonic acid metabolite, PGE2. This tumor can be added to the variety of neoplastic and in¯ammatory processes in which COX-2 is upregulated. Human lesions express COX-2, but surrounding normal marginal tissues in most cases do not. Since it is dicult to determine the surgical margin in aggressive ®bromatosis, it is possible that the few instances in which we found COX-2 expression in the marginal tissue are a result of small tumor cells in the marginal tissues.
Although the normal marginal tissues in the majority of cases did not express COX-2, the primary cell cultures derived from these did. This is in agreement with a recent study showing that mitogenic stimulation of Swiss 3T3 cells results in the expression of COX-2 (Castano et al., 2000) . The expression of COX-2 in our cultures from the cells derived from normal tissues also explains our detection of PGE2 in these cultures (although at lower levels than in aggressive ®broma-tosis cultures) and the decrease in proliferation with COX blocking drugs in these cultures. This demonstrates that COX-2 expression is not limited to proliferating cells from ®bromatoses, but is also present in proliferating ®broblasts, giving support to the concept that COX-2 is expressed by a variety of processes in which there is elevated cell proliferation (Williams et al., 1999) .
b-catenin stabilization in aggressive ®bromatosis results in a higher cell proliferation rate (Li et al., 1998) , perhaps indirectly resulting in upregulation of COX-2. In addition, cells in aggressive ®bromatosis express a variety of cytokines and mitogens, such as platelet derived growth factor (Alman et al., 1995) , which could result in COX-2 upregulation. Alternatively, b-catenin stabilization may more directly regulate COX-2 expression through activation of a lef-tcf transcription factor family member, as has been suggested in colonic neoplasia (Hsi et al., 1999; Mei et al., 1999) . Our transfection studies can not completely distinguish between these two potential mechanisms, since b-catenin mediated tcf dependent transcription likely results in a higher proliferation rate in the cells. However, they do demonstrate that b-catenin mediated tcf-dependent transcription, either directly or indirectly, is responsible for COX-2 regulation.
Despite phenotypic dierences between the murine and human lesions, both demonstrate elevated bcatenin levels. The murine lesions are more prevalent in males, while this is not true in human sporadic cases. The lesions in the mice occur both within the skeletal muscle and super®cial subcutaneous tissues, while in humans the aggressive ®bromatosis is located deep to the super®cial fascia, usually within the skeletal muscle compartments. The human lesions can be quite invasive, often requiring radical, deforming, surgical procedures to treat, while the murine lesions do not grow large enough to cause signi®cant morbidity Alman et al., 1992; Posner et al., 1989) . Elevated b-catenin protein is a universal ®nding in both murine and human aggressive ®bromatoses, giving additional support for b-catenin being the key Number and size of ®bromatoses, along with the standard deviation (stdev) are given, as well as the number and standard deviation (stdev) of gastrointestinal (GI) lesions formed COX-2 in aggressive fibromatosis R Poon et al factor deregulating growth control in this lesion. Although there are a variety of phenotypic dierences between the murine and human lesions, b-catenin elevation in both suggests that the Apc1638N+/7 mouse can be used as a model of the human disease. Pharmacologic blockade of cyclooxygenase resulted in decreased cell proliferation in aggressive ®broma-tosis cell cultures. Both COX-2 selective and COX-2 non-selective agents resulted in the same decrease in cell proliferation, demonstrating that the inhibition of COX-2 is responsible for the decreased cell proliferation in aggressive ®bromatosis. COX-2 blockade resulted in no change in the number of aggressive ®bromatosis formed by the Apc1638N+/7 mouse, but did result in smaller tumors. This is in stark contrast to the number of gastrointestinal lesions formed, which declined to about half the number with COX-2 blockade. The decline in number of gastrointestinal lesions formed with COX-2 blockade is in agreement with prior studies using other murine models of APC induced gastrointestinal neoplasia (Oshima et al., 1996) . Thus, COX-2 does not play a role in the initiation of aggressive ®bromatosis, at least in those predisposed to by APC germ-line mutations, but does play a role in the growth of the lesions.
The mechanism by which COX-2 regulates cell proliferation and tumor size in aggressive ®bromatosis is unclear. Our data does, however, eliminate several potential mechanisms by which COX-2 may exert its eect. Previous investigations suggest that COX-2 modulates apoptosis (Tsujii and DuBois, 1995; Watson, 1998; Wolf and Laster, 1999) . Our data showed a low level of apoptosis in both the human and murine lesions with COX-2 blockade, suggesting that regulation of apoptosis does not play a major role. COX-2 is implicated in the regulation of interactions between colonic neoplasia, and vascular endothelial cells (Tsujii et al., 1998) , perhaps altering tumor vascularity. While this eect can not be completely excluded, it is unlikely that such an interaction plays a major role, as we found no dierence in tumor vascularity with COX-2 blockade. Mechanisms by which COX-2 may regulate proliferation in aggressive ®bromatosis, which we can not exclude, include the activation of prostaglandin receptors, and altering the activity of cell cycle regulatory proteins, such as cyclin D1 (DuBois et al., 1996) .
NSAIDs have anti-tumor eects unrelated to COX inhibition, as demonstrated by studies in COX de®cient cell lines (Hanif et al., 1996; Zhang et al., 1999) . The levels of the NSAIDs used in this study are well within the range reported to have COX independent eects. Although such COX independent mechanisms may play a role in aggressive ®bromatosis, the data from the COX-2 de®cient animals suggests that COX-2 plays at least a partial role in the regulation of tumor size.
The decline in number of gastrointestinal lesions formed, in contrast to the lack of dierence in number of ®bromatoses formed with COX-2 blockade in the Apc1638N+/7 mice, demonstrates that COX-2 plays a role in initiation of gastrointestinal lesions, but not in the initiation of ®bromatoses. One explanation for this may be the expression level of PPAR-d, which is low or absent in aggressive ®bromatosis. Transcriptional activation by PPAR-d may regulate genes important in tumor initiation. Since it is expressed at low levels in aggressive ®bromatoses, these same genes will not be activated. The low level of PPAR-d expression in aggressive ®bromatosis, whose expression has been shown to be upregulated by b-catenin stabilization in colonic neoplasia, further demonstrates that activation of tcf-lef architectural transcription factors will regulate dierent genes in dierent cell types.
This study shows that aggressive ®bromatosis expresses COX-2 and that its blockade will partially decrease cell proliferation, resulting in a slightly smaller tumor size in a murine model. Unlike its eect in colonic neoplasia, COX-2 does not play a role in tumor initiation in aggressive ®bromatosis. Since aggressive ®bromatosis is a locally invasive lesion that does not metastasize, decreasing tumor growth rate could prevent the need for more radical treatments. COX-2 blockade may be an eect adjuvant therapy to help slow tumor growth in aggressive ®bromatosis.
Materials and methods

Human samples and cell cultures
Samples were obtained at the time of surgical resection from sporadic aggressive ®bromatoses involving the extremities in 33 cases. Fibrous tissue from the normal margins of the tumor resections, usually fascial tissue, were also available in 15 of the cases. These tissues were snap frozen and stored in liquid nitrogen vapor for RNA and protein analysis. Sixteen tumors, and normal marginal tissues from six cases were also prepared as primary explant cultures. These were mechanically dissociated and grown as a monolayer, initially in DMEM with 50% fetal calf serum added, but changed to DMEM with 10% fetal calf serum added after 1 week in culture as previously reported (Li et al., 1998) . The cultures were divided when con¯uent, and all studies were performed after this ®rst passage. Mutational analysis for APC and b-catenin in the tumors used in this study was previously reported (Tejpar et al., 1999) . RNA from ®ve human primary colon tumors was used as an additional control for PPAR-d expression studies.
Transgenic mice
The C57B1/6JIco-Apc1638N mice were generated as previously described (Fodde et al., 1994) . Mice develop about 5 ± 6 gastrointestinal lesions by 6 months of age, and male mice develop an average of 45 ®bromatoses by 6 months of age. The females develop a lower number of ®bromatoses than male mice . Mice used were backcrossed to B6 for at least 20 generations. B6,129S-Ptgs2, Cox2 knockout mice (Cox27/7) were obtained from Jackson Laboratories (Bar Harbor, MN, USA). These mice develop renal dysplasia, reducing survival to under 6 months of age (Dinchuk et al., 1995) .
Expression studies in human and murine tissues
Freshly cryopreserved tumor tissue and normal ®brous tissue from the margin of the tumor resections from the same patients were used for RNA and protein studies. Gastrointestinal tumors, ®bromatoses, and normal ®brous tissue (fascial tissue) from 4 month old Apc+/Apc1638N mice were also studied in an identical manner. The SW480 colon cancer cell line (ATCC) was used as a positive control for COX-2 and PPAR-d expression. RNA was extracted using TRIzol reagents according to the manufacturer's instructions (Gibco ± BRL, Grand Island, NY, USA). Protein was extracted from samples by homogenization in lysis buer (1% SDS, 10 mM Tris/Hcl.pH 7.4), followed by centrifugation at 12 000 g for 5 min.
COX-2 expression was analysed using RT ± PCR, Northern analysis and Western analysis. In human tumor cases with sucient RNA available, Northern analysis was performed using a probe generated using PCR with the same primers as for the RT ± PCR analysis. For the remainder of cases, RT ± PCR was performed using speci®c primers for COX-2, and for GAPDH as a house keeping control, using previously published primers and conditions (Gustafson-Svard et al., 1996; Alman et al., 1996) . Human tumors, with sucient case material available, and murine tumors were analysed using Western analysis. Total protein was electrophoresed on an SDS polyacrylamide gel, transferred to a polyvinylidene di¯uoride membrane. Western blot was performed using an antibody to COX-2 (Signal Transduction Laboratories). Hybridization was carried out overnight at 48C and detected using an IgG-horseradish peroxidase secondary antibody and chemiluminescence. The membrane was then stripped and Western blot performed using an anti-actin antibody (Monoclonal anti-actin, clone no. AC-40, Sigma), as a control for protein loading.
b-catenin expression level was compared between tumor and normal tissues derived from Apc+/Apc1638N mice using Western analysis, with a b-catenin antibody (Transduction Laboratories, Lexington, KY, USA) as previously reported (Alman et al., 1997b) . Paran embedded, formalin ®xed material from the murine lesions were used for b-catenin immunohistochemistry as previously reported (Tejpar et al., 1999; Alman et al., 1997b) . PPAR-delta expression was determined in human and murine lesions and normal murine tissues using RT ± PCR, with the upstream primer 5'-AGAAGAGGAAGCTGGTGGC (at nucleotide 452) and the downstream primer 5'-TTCTGCCAGCAGCTTGGGGA (at nucleotide 1202), at an annealing temperature of 578C (Schmidt et al., 1992) , using a probe generated from the PCR products. Northern analysis of expression was performed in cases with sucient RNA available. The primary human colon cancer RNA was used as an additional control.
COX-2 inhibitors in human cell cultures
Three COX inhibitors were utilized in the cell culture studies. Two were the non-selective inhibitors, Sulindac (Sigma Chemical Co, St Louis, MO, USA) and Indomethacin (Oxford Biomedical Research, Rochester Hill, MI, USA). The third agent was the COX-2 selective agent, DFU (Merck Frosst, Quebec, Canada). The highest concentration of each drug used in the cell culture experiments was chosen as the concentration blocking 100% of COX-2 activity in vitro from a previous dose-response study (Chan et al., 1997) . The drugs were utilized at concentrations of 420 mM to 420 nM for Sulindac, 260 mM to 260 nM for Indomethacin, and 410 mM to 410 nM for DFU. All of the drugs were diluted in DMSO, and the same concentration of DMSO was added to cultures as a carrier control. To determine if the eect of the various drugs was reversible, an additional experiment was performed in which each cell type was treated with the highest concentration of each drug, washed, and then grown with 10% fetal calf serum in the media for an additional 24 h, followed by determination of cell proliferation. Prostaglandin E2 level was measured for each cell type, drug, and drug concentration using a competitive enzyme assay (Cayman), as previously reported (Erickson et al., 1999) . Cells were plated onto 24 well plates, then plated with either media, or media containing one of the drugs at one of the various doses for 12 h. Media was removed and PGE2 measurement was performed in duplicate for each sample according to the manufacturer's instructions.
Cell cultures from 16 aggressive ®bromatoses and normal ®broblasts from six of these cases were tested after their ®rst passage in culture. They were grown to 40% con¯uence, and then media changed to include either one of the three COX blocking agents at various concentrations, or carrier as a control. Cells were grown in the media with additives for 24 h and then prepared for analysis for proliferation and apoptosis. Proliferation was measured using bromodexyuridine incoporation detected by an enzyme-linked immunoassay (Cell proliferation ELISA, BrDU, Boehringer-Mannheim, Mannheim, Germany). Apoptosis was measured using DNA laddering (Apoptotic DNA Ladder, Boehringer-Mannheim, Mannheim, Germany), and terminal deoxynucleotidly transferase-mediated dUTP nick-end labeling (TUNEL), carried out according to manufacturer's (Boehringer Mannheim, Mannheim, Germany) recommendations. Proliferation was expressed as a ratio relative to the proliferative rate without any drug added. Each of the drug concentrations was tested on each of the cell cultures and control cells in triplicate. For the apoptosis experiments, cells were also grown with ten times the maximum concentration of each of the drugs as used for the proliferation experiments. The two way t-test was used for statistical analysis of the results.
Regulation of COX-2 expression in vitro
Cell cultures were derived from an aggressive ®bromatosis, and transfected with either a dominant negative form of tcf (DN-tcf-4E), which will bind to the tcf consensus sequence, but prevents transcriptional activation (Tetsu and McCormick, 1999) , or an empty vector. Extracted RNA was analysed for expression of COX-2 and GAPDH as a control using Northern analysis. To determine if COX-2 expression varied with proliferation in ®broblasts, COX-2 expression was determined from the cultures derived from normal marginal tissues during the log phase of growth, at con¯uence and after serum starvation (same media without fetal calf serum for 12 h) using RT ± PCR.
Blockade of COX-2 in vivo in Apc+/Apc1638N mice Apc+/Apc1638N male mice were crossed with Cox-27/7 female mice. The resulting compound heterozygote Apc+/ Apc1638N-Cox-2+/7 mice were crossed with Cox-2+/7 animals, producing Apc+/Apc1638N-Cox27/7 and Apc+/ Apc1638N-Cox2+/+ mice. Sixteen mice of each genotype (eight male and eight female) were studied. They were sacri®ced at 4 months of age, and number and size of ®bromatoses and gastro-intestinal lesions scored as previously reported . A total of 83 male and 79 female B6-Apc+/Apc1638N mice were assigned to either nodrug, sulindac, DFU, or MF-tricyclic (Chan et al., 1997; Black et al., 1998) to begin after weaning. These drugs were fed to the mice in food pellets at a concentration of 0.00667% (Merck Frosst, Quebec, Canada) . The mice were fed the various diets until they were 6 months of age, sacri®ced and analysed for gastrointestinal lesions and ®bromatoses. Before sacri®ce, serum levels of the drugs were determined using an immunoassay as previously reported (Black et al,. 1998; Oshima et al., 1996) in ®ve mice in each treatment group. The drugs were present at therapeutic levels in the Sulindac and MF-tricyclic group (0.41 mg/ml and 0.48 mg/ml respectively). DFU was only present at a negligible level in the mice tested.
Analysis of murine fibromatoses
One ®bromatosis from each of the Apc+/Apc1638N-Cox27/ 7 and each of the Apc+/Apc1638N-Cox2+/+ mice was analysed for apoptosis, vascularity, and proliferation using immunohistochemical techniques. Sections were embedded in OCT and snap frozen. Terminal deoxynucleotidyl transferasemediated dUTP nick-end labeling (TUNEL) was carried out according to manufacturer's (Boehringer ± Mannheim, Mannheim, Germany) recommendations. Additional slides were immunostained using a factor VIII antibody and MIB-1 antibody to determine tumor vascularity and proliferation. Slides were blindly graded for per cent of positively stained cells using each of the antibodies.
